Zejula 200 Pill - blue oval, 16mm
Generic Name: niraparib
Pill with imprint Zejula 200 is Blue, Oval and has been identified as Zejula 200 mg. It is supplied by GlaxoSmithKline.
Zejula is used in the treatment of Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer and belongs to the drug class PARP inhibitors. Zejula 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Zejula 200
Zejula
- Generic Name
- niraparib
- Imprint
- Zejula 200
- Strength
- 200 mg
- Color
- Blue
- Size
- 16.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- PARP inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- GlaxoSmithKline
- National Drug Code (NDC)
- 00173-0912
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Gemcitabine
Gemcitabine is used for breast cancer, breast cancer, metastatic, nasopharyngeal carcinoma, non ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Bevacizumab
Bevacizumab injection is a targeted cancer drug used to treat types of non-small cell lung cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
More about Zejula (niraparib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (58)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PARP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.